Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W DE Boer

Showing results (191-200 of 490) with videos related to

Pageof 49
Sort By:
Case Reports in Gastroenterology|July 10, 2026
Necrotizing Pancreatitis and Endovascular Stenting of the Portal and Superior Mesenteric Vein: A Case ReportLars J M de Lange, Hanne C R Verberght, Thomas J G R De Clercq, et al.
Family Practice|September 5, 2025
Feasibility of implementing an intervention in general practice for deprescribing of glucose-lowering medication in overtreated elderlyCharlotte Andriessen, Marieke T Blom, Beryl A C E van Hoek, et al.
Transfusion|May 12, 2025
Vesiculation as potential novel pathogenic mechanism in autoimmune hemolytic anemiaEsther C W de Boer, Femke V M Mulder, Silvia Neri, et al.
Cancers|November 25, 2023
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related ToxicitiesJanneke W de Boer, Kylie Keijzer, Elise R A Pennings, et al.
Trials|July 25, 2024
A deprescribing programme aimed to optimise blood glucose-lowering medication in older people with type 2 diabetes mellitus, the OMED2-study: the study protocol for a randomised controlled trialCharlotte Andriessen, Marieke T Blom, Beryl A C E van Hoek, et al.
Blood Advances|August 28, 2023
Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapyJanneke W de Boer, Elise R A Pennings, Ankie Kleinjan, et al.
Nature Communications|November 25, 2025
Whole-body CD8<sup>+</sup> T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 studyJanneke W de Boer, Kylie Keijzer, Jaap A van Doesum, et al.
Nature Communications|February 10, 2026
Author Correction: Whole-body CD8<sup>+</sup> T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 studyJanneke W de Boer, Kylie Keijzer, Jaap A van Doesum, et al.
Journal of Endovascular Therapy : an Official Journal of the International Society of Endovascular Specialists|August 11, 2017
Short-term Results of the RAPID Randomized Trial of the Legflow Paclitaxel-Eluting Balloon With Supera Stenting vs Supera Stenting Alone for the Treatment of Intermediate and Long Superficial Femoral Artery LesionsSanne W de Boer, Daniel A F van den Heuvel, Debbie A B de Vries-Werson, et al.
Blood Advances|July 16, 2025
Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections and survival after CART in R/R LBCLJanneke W. de Boer, Kylie Keijzer, Suzanne van Dorp, et al.
Pageof 49

Showing results (191-200 of 490) with videos related to

Sort By:
Pageof 49
Case Reports in Gastroenterology|July 10, 2026
Necrotizing Pancreatitis and Endovascular Stenting of the Portal and Superior Mesenteric Vein: A Case ReportLars J M de Lange, Hanne C R Verberght, Thomas J G R De Clercq, et al.
Family Practice|September 5, 2025
Feasibility of implementing an intervention in general practice for deprescribing of glucose-lowering medication in overtreated elderlyCharlotte Andriessen, Marieke T Blom, Beryl A C E van Hoek, et al.
Transfusion|May 12, 2025
Vesiculation as potential novel pathogenic mechanism in autoimmune hemolytic anemiaEsther C W de Boer, Femke V M Mulder, Silvia Neri, et al.
Cancers|November 25, 2023
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related ToxicitiesJanneke W de Boer, Kylie Keijzer, Elise R A Pennings, et al.
Trials|July 25, 2024
A deprescribing programme aimed to optimise blood glucose-lowering medication in older people with type 2 diabetes mellitus, the OMED2-study: the study protocol for a randomised controlled trialCharlotte Andriessen, Marieke T Blom, Beryl A C E van Hoek, et al.
Blood Advances|August 28, 2023
Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapyJanneke W de Boer, Elise R A Pennings, Ankie Kleinjan, et al.
Nature Communications|November 25, 2025
Whole-body CD8<sup>+</sup> T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 studyJanneke W de Boer, Kylie Keijzer, Jaap A van Doesum, et al.
Nature Communications|February 10, 2026
Author Correction: Whole-body CD8<sup>+</sup> T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 studyJanneke W de Boer, Kylie Keijzer, Jaap A van Doesum, et al.
Journal of Endovascular Therapy : an Official Journal of the International Society of Endovascular Specialists|August 11, 2017
Short-term Results of the RAPID Randomized Trial of the Legflow Paclitaxel-Eluting Balloon With Supera Stenting vs Supera Stenting Alone for the Treatment of Intermediate and Long Superficial Femoral Artery LesionsSanne W de Boer, Daniel A F van den Heuvel, Debbie A B de Vries-Werson, et al.
Blood Advances|July 16, 2025
Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections and survival after CART in R/R LBCLJanneke W. de Boer, Kylie Keijzer, Suzanne van Dorp, et al.
Pageof 49